adefovir dipivoxil + indinavir + stavudine

This drug is a fixed-dose combination of three antiretroviral agents: **adefovir dipivoxil**, **indinavir**, and **stavudine**. - **Adefovir dipivoxil** is a nucleotide analog prodrug that, once converted in the body to adefovir, is phosphorylated to adefovir diphosphate. This active metabolite inhibits viral DNA polymerases (including HBV and HIV reverse transcriptase) by causing chain termination and blocking DNA synthesis[2][4]. - **Indinavir** is a small molecule inhibitor of HIV-1 protease, an enzyme essential for proteolytic cleavage of HIV Gag-Pol polyprotein, resulting in the production of immature, noninfectious virus particles. - **Stavudine**, also known as D4T, is a nucleoside reverse transcriptase inhibitor (NRTI); its active phosphorylated form inhibits the activity of HIV reverse transcriptase by chain termination of viral DNA. This combination would target viral replication at multiple steps for HIV (potentially also HBV, due to adefovir’s spectrum)[2][4]. There is, however, no evidence of an approved or marketed product specifically containing this triple combination, suggesting it might be an investigational or theoretical formulation rather than a standard or branded product.